Mekori Y A, Karin N, Gottesman G, Cohen I R
Allergy-Immunology Unit, Meir Hospital, Rehovot, Israel.
Eur J Immunol. 1990 Sep;20(9):2083-7. doi: 10.1002/eji.1830200929.
It was shown previously that experimental autoimmune diseases could be prevented or treated specifically by administering suitably attenuated autoimmune T lymphocytes to animals, a process termed T cell vaccination (Cohen, I. R., Sci. American 1988. 256: 52). We now report that T cell vaccination is an effective way of inducing tolerance to contact sensitivity to simple chemical haptens. Vaccines were prepared from populations of lymph node cells from specifically sensitized mice by activating the T cells with the T cell mitogen concanavalin A and then treating the T cell blasts with glutaraldehyde. The vaccinated mice showed decreased delayed sensitivity responses to the specific sensitizing antigen and developed significant delayed sensitivity responses to the T cells of the same specificity as those used for vaccination. Thus, T cell vaccination against contact sensitivity reactions appears to function similarly to T cell vaccination against autoimmune disease.
先前的研究表明,通过给动物注射适当减毒的自身免疫性T淋巴细胞,可以特异性地预防或治疗实验性自身免疫性疾病,这一过程称为T细胞疫苗接种(科恩,I.R.,《科学美国人》1988年。256:52)。我们现在报告,T细胞疫苗接种是诱导对简单化学半抗原接触敏感性产生耐受性的有效方法。通过用T细胞促有丝分裂剂刀豆球蛋白A激活T细胞,然后用戊二醛处理T细胞母细胞,从特异性致敏小鼠的淋巴结细胞群体中制备疫苗。接种疫苗的小鼠对特异性致敏抗原的迟发型超敏反应降低,并对与用于接种疫苗的T细胞具有相同特异性的T细胞产生显著的迟发型超敏反应。因此,针对接触敏感性反应的T细胞疫苗接种似乎与针对自身免疫性疾病的T细胞疫苗接种作用相似。